A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
StandardStandard
A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention. / Hughes, D.; Guzauskas, G.F.; Hughes, D.A. et al.
Yn: Clinical Pharmacology and Therapeutics, 28.03.2012.
Yn: Clinical Pharmacology and Therapeutics, 28.03.2012.
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid
HarvardHarvard
Hughes, D, Guzauskas, GF, Hughes, DA, Bradley, SM & Veenstra, DL 2012, 'A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention', Clinical Pharmacology and Therapeutics. https://doi.org/10.1038/clpt.2011.303
APA
Hughes, D., Guzauskas, G. F., Hughes, D. A., Bradley, S. M., & Veenstra, D. L. (2012). A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention. Clinical Pharmacology and Therapeutics. https://doi.org/10.1038/clpt.2011.303
CBE
Hughes D, Guzauskas GF, Hughes DA, Bradley SM, Veenstra DL. 2012. A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention. Clinical Pharmacology and Therapeutics. https://doi.org/10.1038/clpt.2011.303
MLA
Hughes, D. et al. "A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention". Clinical Pharmacology and Therapeutics. 2012. https://doi.org/10.1038/clpt.2011.303
VancouverVancouver
Hughes D, Guzauskas GF, Hughes DA, Bradley SM, Veenstra DL. A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention. Clinical Pharmacology and Therapeutics. 2012 Maw 28. doi: 10.1038/clpt.2011.303
Author
RIS
TY - JOUR
T1 - A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention
AU - Hughes, D.
AU - Guzauskas, G.F.
AU - Hughes, D.A.
AU - Bradley, S.M.
AU - Veenstra, D.L.
PY - 2012/3/28
Y1 - 2012/3/28
U2 - 10.1038/clpt.2011.303
DO - 10.1038/clpt.2011.303
M3 - Article
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
SN - 0009-9236
ER -